# BAX catalysts: BAXTER INTERNATIONAL INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bax/catalysts

> BAXTER INTERNATIONAL INC (BAX) has no upcoming catalysts in this calendar. The latest recorded is the Sodium Bicarbonate (sodium bicarbonate) FDA approval, August 14, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | BAXTER INTERNATIONAL INC |
| Ticker | BAX (NYSE) |
| SEC CIK | 10456 |
| SIC | 3841 |
| SEC filings | https://sec-api.dev/companies/bax |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 20, 2017 | [Clindamycin Phosphate In 0.9% Sodium Chloride (clindamycin phosphate) FDA approval](https://sec-api.dev/pdufa/clindamycin) | BAX |  | completed, approved | "NDA208083 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20170420, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE (CLINDAMYCIN PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208083%22)) |
| December 21, 2017 | [Bivalirudin In 0.9% Sodium Chloride (bivalirudin) FDA approval](https://sec-api.dev/pdufa/bivalirudin) | BAX |  | completed, approved | "NDA208374 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20171221, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product BIVALIRUDIN IN 0.9% SODIUM CHLORIDE (BIVALIRUDIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208374%22)) |
| June 20, 2019 | [Myxredlin (insulin human) FDA approval](https://sec-api.dev/pdufa/insulin-human) | BAX |  | completed, approved | "BLA208157 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20190620, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product MYXREDLIN (INSULIN HUMAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA208157%22)) |
| December 13, 2019 | [Nouress (cysteine hydrochloride) FDA approval](https://sec-api.dev/pdufa/cysteine) | BAX |  | completed, approved | "NDA212535 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20191213, review_priority PRIORITY; sponsor_name BAXTER HLTHCARE CORP; product NOURESS (CYSTEINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212535%22)) |
| January 15, 2021 | [Norepinephrine Bitartrate In 0.9% Sodium Chloride (norepinephrine bitartrate) FDA approval](https://sec-api.dev/pdufa/norepinephrine) | BAX |  | completed, approved | "NDA214313 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20210115, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214313%22)) |
| February 1, 2021 | [Cefazolin In Dextrose (cefazolin sodium) label expansion decision](https://sec-api.dev/pdufa/cefazolin) | BAX |  | completed, approved | "NDA207131 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210201, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product CEFAZOLIN IN DEXTROSE (CEFAZOLIN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207131%22)) |
| April 29, 2021 | [Daptomycin (daptomycin) complete response letter (CRL)](https://sec-api.dev/pdufa/daptomycin) | BAX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22213645_2022_Orig1s000OtherActionLtrs.pdf%22)) |
| January 25, 2022 | [Daptomycin (daptomycin) FDA approval](https://sec-api.dev/pdufa/daptomycin) | BAX |  | completed, approved | "NDA213645 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20220125, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product DAPTOMYCIN IN 0.9% SODIUM CHLORIDE (DAPTOMYCIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213645%22)) |
| February 27, 2023 | [Daptomycin (daptomycin) label expansion decision](https://sec-api.dev/pdufa/daptomycin) | BAX |  | completed, approved | "NDA213645 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20230227, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product DAPTOMYCIN IN 0.9% SODIUM CHLORIDE (DAPTOMYCIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213645%22)) |
| June 27, 2023 | [Cyclophosphamide (cyclophosphamide) FDA approval](https://sec-api.dev/pdufa/cyclophosphamide) | BAX |  | completed, approved | "NDA217651 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230627, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217651%22)) |
| September 29, 2023 | [Micafungin In Sodium Chloride 0.9% (micafungin sodium) FDA approval](https://sec-api.dev/pdufa/micafungin) | BAX |  | completed, approved | "NDA216142 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230929, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product MICAFUNGIN IN SODIUM CHLORIDE 0.9% (MICAFUNGIN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216142%22)) |
| September 29, 2023 | [Vasopressin In Sodium Chloride 0.9% (vasopressin) FDA approval](https://sec-api.dev/pdufa/vasopressin) | BAX |  | completed, approved | "NDA217569 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230929, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product VASOPRESSIN IN SODIUM CHLORIDE 0.9% (VASOPRESSIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217569%22)) |
| February 1, 2024 | [Cefazolin In Dextrose (cefazolin sodium) label expansion decision](https://sec-api.dev/pdufa/cefazolin) | BAX |  | completed, approved | "NDA207131 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20240201, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product CEFAZOLIN IN DEXTROSE (CEFAZOLIN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207131%22)) |
| February 14, 2024 | [Protonix Iv (pantoprazole sodium) FDA approval](https://sec-api.dev/pdufa/pantoprazole) | BAX |  | completed, approved | "NDA217512 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240214, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE (PANTOPRAZOLE SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217512%22)) |
| March 27, 2024 | [Nda218408 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218408) | BAX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218408_20240327.pdf%22)) |
| March 29, 2024 | [Nda218224 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218224) | BAX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218524_20240329.pdf%22)) |
| April 24, 2024 | [Clinolipid 20% (olive oil; soybean oil) label expansion decision](https://sec-api.dev/pdufa/olive-oil-soybean-oil) | BAX |  | completed, approved | "NDA204508 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20240424, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product CLINOLIPID 20% (OLIVE OIL; SOYBEAN OIL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204508%22)) |
| May 31, 2024 | [Cefazolin In Dextrose (cefazolin sodium) label expansion decision](https://sec-api.dev/pdufa/cefazolin) | BAX |  | completed, approved | "NDA207131 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20240531, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product CEFAZOLIN IN DEXTROSE (CEFAZOLIN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207131%22)) |
| February 28, 2025 | [Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) FDA approval](https://sec-api.dev/pdufa/epinephrine) | BAX |  | completed, approved | "NDA218475 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250228, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (EPINEPHRINE BITARTRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218475%22)) |
| March 30, 2026 | [Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) FDA approval](https://sec-api.dev/pdufa/epinephrine) | BAX |  | completed, approved | "NDA220626 ORIG-1 (New Combination and New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260330, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product EPINEPHRINE (EPINEPHRINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220626%22)) |
| August 14, 2026 | [Sodium Bicarbonate (sodium bicarbonate) FDA approval](https://sec-api.dev/pdufa/bicarbonate) | BAX |  | completed, approved | "NDA218524 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260814, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product SODIUM BICARBONATE (SODIUM BICARBONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218524%22)) |

## Drugs

- [Sodium Bicarbonate (sodium bicarbonate)](https://sec-api.dev/pdufa/bicarbonate): 
- [Bivalirudin In 0.9% Sodium Chloride (bivalirudin)](https://sec-api.dev/pdufa/bivalirudin): 
- [Cefazolin In Dextrose (cefazolin sodium)](https://sec-api.dev/pdufa/cefazolin): 
- [Clindamycin Phosphate In 0.9% Sodium Chloride (clindamycin phosphate)](https://sec-api.dev/pdufa/clindamycin): 
- [Nouress (cysteine hydrochloride)](https://sec-api.dev/pdufa/cysteine): 
- [Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate)](https://sec-api.dev/pdufa/epinephrine): 
- [Myxredlin (insulin human)](https://sec-api.dev/pdufa/insulin-human): 
- [Micafungin In Sodium Chloride 0.9% (micafungin sodium)](https://sec-api.dev/pdufa/micafungin): 
- [Nda218224](https://sec-api.dev/pdufa/nda218224): 
- [Nda218408](https://sec-api.dev/pdufa/nda218408): 
- [Norepinephrine Bitartrate In 0.9% Sodium Chloride (norepinephrine bitartrate)](https://sec-api.dev/pdufa/norepinephrine): 
- [Clinolipid 20% (olive oil; soybean oil)](https://sec-api.dev/pdufa/olive-oil-soybean-oil): 
- [Vasopressin In Sodium Chloride 0.9% (vasopressin)](https://sec-api.dev/pdufa/vasopressin): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bax/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BAX catalysts: BAXTER INTERNATIONAL INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bax/catalysts

```bibtex
@misc{secapidev_companies_bax_catalysts_20261116,
  title        = {BAX catalysts: BAXTER INTERNATIONAL INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bax/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bax_catalysts_20261116","title":"BAX catalysts: BAXTER INTERNATIONAL INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bax/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
